71.63 USD
-0.9 (-1.24%)
At close: Feb 3, 2026
71.9 USD
+0.27 (+0.38%)
After Hours: 2/3/2026, 8:11:41 PM
DXCM gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. DXCM scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DXCM is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make DXCM suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year DXCM was profitable.
- DXCM had a positive operating cash flow in the past year.
- In the past 5 years DXCM has always been profitable.
- Each year in the past 5 years DXCM had a positive operating cash flow.
1.2 Ratios
- DXCM has a Return On Assets of 9.61%. This is amongst the best in the industry. DXCM outperforms 93.01% of its industry peers.
- Looking at the Return On Equity, with a value of 26.44%, DXCM belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
- The Return On Invested Capital of DXCM (15.72%) is better than 95.70% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for DXCM is above the industry average of 8.80%.
- The 3 year average ROIC (11.25%) for DXCM is below the current ROIC(15.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 26.44% | ||
| ROIC | 15.72% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
- DXCM has a Profit Margin of 15.96%. This is amongst the best in the industry. DXCM outperforms 93.01% of its industry peers.
- In the last couple of years the Profit Margin of DXCM has grown nicely.
- Looking at the Operating Margin, with a value of 18.41%, DXCM belongs to the top of the industry, outperforming 90.32% of the companies in the same industry.
- DXCM's Operating Margin has improved in the last couple of years.
- DXCM has a better Gross Margin (60.20%) than 61.29% of its industry peers.
- DXCM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.41% | ||
| PM (TTM) | 15.96% | ||
| GM | 60.2% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DXCM is creating some value.
- The number of shares outstanding for DXCM has been increased compared to 1 year ago.
- DXCM has more shares outstanding than it did 5 years ago.
- DXCM has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.18 indicates that DXCM is not in any danger for bankruptcy at the moment.
- DXCM's Altman-Z score of 5.18 is fine compared to the rest of the industry. DXCM outperforms 77.42% of its industry peers.
- DXCM has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as DXCM would need 2.36 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 2.36, DXCM belongs to the best of the industry, outperforming 85.48% of the companies in the same industry.
- DXCM has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
- DXCM has a Debt to Equity ratio (0.47) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 5.18 |
ROIC/WACC1.61
WACC9.75%
2.3 Liquidity
- DXCM has a Current Ratio of 1.56. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.56, DXCM is not doing good in the industry: 70.97% of the companies in the same industry are doing better.
- DXCM has a Quick Ratio of 1.38. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.38, DXCM is in line with its industry, outperforming 40.32% of the companies in the same industry.
- The current and quick ratio evaluation for DXCM is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
- DXCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.41%, which is quite good.
- Measured over the past years, DXCM shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
- Looking at the last year, DXCM shows a quite strong growth in Revenue. The Revenue has grown by 14.21% in the last year.
- Measured over the past years, DXCM shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)9.41%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%35.56%
Revenue 1Y (TTM)14.21%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%21.64%
3.2 Future
- The Earnings Per Share is expected to grow by 22.05% on average over the next years. This is a very strong growth
- Based on estimates for the next years, DXCM will show a quite strong growth in Revenue. The Revenue will grow by 13.28% on average per year.
EPS Next Y27.38%
EPS Next 2Y23.51%
EPS Next 3Y22.59%
EPS Next 5Y22.05%
Revenue Next Year15.45%
Revenue Next 2Y14.08%
Revenue Next 3Y13.66%
Revenue Next 5Y13.28%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- DXCM is valuated quite expensively with a Price/Earnings ratio of 38.51.
- Based on the Price/Earnings ratio, DXCM is valued a bit cheaper than 70.97% of the companies in the same industry.
- When comparing the Price/Earnings ratio of DXCM to the average of the S&P500 Index (28.18), we can say DXCM is valued slightly more expensively.
- The Price/Forward Earnings ratio is 28.46, which means the current valuation is very expensive for DXCM.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of DXCM indicates a somewhat cheap valuation: DXCM is cheaper than 72.58% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of DXCM to the average of the S&P500 Index (25.51), we can say DXCM is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.51 | ||
| Fwd PE | 28.46 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, DXCM is valued a bit cheaper than the industry average as 73.66% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of DXCM indicates a rather cheap valuation: DXCM is cheaper than 82.80% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.31 | ||
| EV/EBITDA | 23.83 |
4.3 Compensation for Growth
- DXCM's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- DXCM has an outstanding profitability rating, which may justify a higher PE ratio.
- DXCM's earnings are expected to grow with 22.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.41
PEG (5Y)1.32
EPS Next 2Y23.51%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
- DXCM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
71.63
-0.9 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners99.77%
Inst Owner Change-4.27%
Ins Owners0.19%
Ins Owner Change0.62%
Market Cap27.94B
Revenue(TTM)4.52B
Net Income(TTM)720.70M
Analysts85.95
Price Target87.62 (22.32%)
Short Float %3.98%
Short Ratio2.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.05%
Min EPS beat(2)5.32%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)4.61%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)11
Avg EPS beat(16)6.53%
Revenue beat(2)2
Avg Revenue beat(2)0.74%
Min Revenue beat(2)0.61%
Max Revenue beat(2)0.88%
Revenue beat(4)2
Avg Revenue beat(4)0.02%
Min Revenue beat(4)-1.2%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.92%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)-1.03%
PT rev (3m)-14.2%
EPS NQ rev (1m)0.41%
EPS NQ rev (3m)-4.21%
EPS NY rev (1m)0.07%
EPS NY rev (3m)0.45%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.51 | ||
| Fwd PE | 28.46 | ||
| P/S | 6.19 | ||
| P/FCF | 26.31 | ||
| P/OCF | 19.29 | ||
| P/B | 10.25 | ||
| P/tB | 10.65 | ||
| EV/EBITDA | 23.83 |
EPS(TTM)1.86
EY2.6%
EPS(NY)2.52
Fwd EY3.51%
FCF(TTM)2.72
FCFY3.8%
OCF(TTM)3.71
OCFY5.18%
SpS11.58
BVpS6.99
TBVpS6.73
PEG (NY)1.41
PEG (5Y)1.32
Graham Number17.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 26.44% | ||
| ROCE | 19.96% | ||
| ROIC | 15.72% | ||
| ROICexc | 77.75% | ||
| ROICexgc | 88.6% | ||
| OM | 18.41% | ||
| PM (TTM) | 15.96% | ||
| GM | 60.2% | ||
| FCFM | 23.51% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 158.02% | ||
| Cap/Sales | 8.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 134.63% | ||
| Profit Quality | 147.34% | ||
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.38 | ||
| Altman-Z | 5.18 |
F-Score5
WACC9.75%
ROIC/WACC1.61
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)9.41%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%35.56%
EPS Next Y27.38%
EPS Next 2Y23.51%
EPS Next 3Y22.59%
EPS Next 5Y22.05%
Revenue 1Y (TTM)14.21%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%21.64%
Revenue Next Year15.45%
Revenue Next 2Y14.08%
Revenue Next 3Y13.66%
Revenue Next 5Y13.28%
EBIT growth 1Y28.95%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year73.63%
EBIT Next 3Y36.37%
EBIT Next 5Y30.77%
FCF growth 1Y112.47%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y93.75%
OCF growth 3Y30.77%
OCF growth 5Y25.76%
DEXCOM INC / DXCM FAQ
Can you provide the ChartMill fundamental rating for DEXCOM INC?
ChartMill assigns a fundamental rating of 7 / 10 to DXCM.
Can you provide the valuation status for DEXCOM INC?
ChartMill assigns a valuation rating of 5 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.
Can you provide the profitability details for DEXCOM INC?
DEXCOM INC (DXCM) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for DXCM stock?
The Price/Earnings (PE) ratio for DEXCOM INC (DXCM) is 38.51 and the Price/Book (PB) ratio is 10.25.